Table 3. Results of a multivariate logistic regression model with presence of HER-positive CTCs (yes/no) as binary response variable (n = 248 patients; 10 patients were excluded from the multivariate analysis because of missing values).

Clinical variable at baseline	Odds ratio	95% Confidence interval	P-value
pT			0.370
pT2 vs. pT1	0.15	0.67–1.98	0.612
pT3 vs. pT1	2.26	0.44–11.58	0.328
pT4 vs. pT1	0.21	0.02–2.03	0.177
pN			0.541
pN+ vs pN0	0.85	0.49–1.45	0.541
Histology			0.036
lobular vs. ductal	0.41	0.10–1.75	0.229
other vs. ductal	1.73	1.00–3.01	0.052
Grading			0.913
G2 vs. G1	0.73	0.04–14.24	0.835
G3 vs. G1	0.66	0.03–12.92	0.782
ER status			0.710
positive vs. negative	1.16	0.53–2.52	0.710
PR status			0.337
positive vs. negative	0.69	0.32–1.48	0.337
Menopause			0.087
post- vs. pre-    menopausal	0.47	0.20–1.12	0.087
Age (years)			0.634
≥ 50 vs. < 50	1.23	0.52–2.92	0.634
Chemotherapy			0.166
FEC-D vs. FEC-DG	0.686	0.40–1.17	0.166

FEC-DG = epirubicin-fluorouracil-cyclophosphamide/gemcitabine-docetaxel chemotherapy

FEC-D = epirubicin-fluorouracil-cyclophosphamide docetaxel (D) chemotherapy